Komori
H

Human Metabolome Technologies,Inc.

6090Information and Communications, Services and OthersMicro cap
596JPY-3.6%
★ Watch (sign-up required)
Price history
¥596Latest-4.2%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

Established as a venture originating from Keio University, our Group provides research and development support for pharmaceutical development, disease diagnosis, food development and other applications, centered on metabolome analysis technology that comprehensively measures metabolites in living organisms. As a bioanalysis platform provider, we also offer solutions supporting the entire process from research and development through production efficiency improvements, quality assurance and testing. We have sales subsidiaries in the European and U.S. markets and support customers’ research and development by combining three service areas: Life Science Support Services (LSS), which leverage our proprietary technologies and expertise centered on CE-MS methods; Functional material Development Support Services (FDS); and Bio Manufacturing Support Services (BMS). We are also working to improve productivity through the use of AI in the digital biology era, with the aim of enhancing corporate value by expanding our business domains and improving productivity.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 20
PER
17.76How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
1.94How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
10.9%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥3.6bnShare price × number of shares. The value of the entire company.
Equity ratio
80.2%The proportion of assets funded by money that does not have to be repaid.
Operating margin
14.7%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
3.0%The average annual growth in sales over the past three years.
What to watch next
鶴岡本社：解析用分析装置等の新設（着手2026年7月、完成予定2027年6月）による処理能力/稼働率の改善
Around June 2027Impact MediumLikelihood Medium
新規事業：ヘルスケア検査受託サービスの開始計画（2027年6月期に開始予定）
Fiscal year ending June 2027Impact HighLikelihood Medium
生産性向上施策の実装（AI活用・ロボット活用・業務平準化）と、減価償却費増を上回る利益改善の確認
Second half of 2026 to 2027Impact MediumLikelihood Medium
クリニック向けNAD+検査事業の提携（Rhelixa）で、ヘルスケア領域の新規売上が伸びるか
提携後の売上計上状況次第（目安：2026年下期〜2027年）Impact MediumLikelihood Low
What to watch next
Loading
Who owns itTop holders total 35.3%
Listed holders 35.3%Everyone else 64.8%
Tomita Masaru (冨田 勝)7.20%
MSIP CLIENT SECURITIES4.04%
M3,Inc.4.01%
Soga Tomoyoshi (曽我 朋義)3.84%
The Dai-ichi Life Insurance Company, Limited3.43%
西岡 孝明2.77%
The Yamagata Bank,Ltd.2.77%
株式会社荘内銀行2.77%
2 other listed holders4.42%
Who owns it
HolderOwnership (%)
Tomita Masaru (冨田 勝)7.20
MSIP CLIENT SECURITIES4.04
M3,Inc.4.01
Soga Tomoyoshi (曽我 朋義)3.84
The Dai-ichi Life Insurance Company, Limited3.43
西岡 孝明2.77
The Yamagata Bank,Ltd.2.77
株式会社荘内銀行2.77
2 other listed holders4.42
This company's documents
Filings
Timely disclosures
Threads